did anyone else see the news today on Bristol trial? link inside..
Karen said
Aug 3, 2012
Here is the email I received today on the Bristol trial...
8:49 AM Bristol-Myers Squibb suspended its study of a drug intended to treat liver disease hepatitis C after a patient suffered heart failure, raising questions about the drug's potential and the $2.5B it paid earlier this year to buy the company that developed it.
Aug 1 (Reuters) - Bristol-Myers Squibb Co said it has stopped administering an experimental drug to treat hepatitis C in a mid-stage trial due to a serious safety issue.
The cause of the safety issue and any potential relationship to the drug, known as BMS-986094, was not known, it said in a statement.
The company said it was undertaking an immediate assessment of all patients involved in the study and following an evaluation of patient data, will take appropriate action.
Bristol Myers acquired BMS-986094 through its $2.5 billion purchase of Inhibitex Inc earlier this year.
The drug belongs to a promising new type of hepatitis C medicines called nucleotide polymerase inhibitors, which work by targeting polymerase -- an enzyme essential for replication of the hepatitis C virus.
Here is the email I received today on the Bristol trial...
8:49 AM Bristol-Myers Squibb suspended its study of a drug intended to treat liver disease hepatitis C after a patient suffered heart failure, raising questions about the drug's potential and the $2.5B it paid earlier this year to buy the company that developed it.
http://in.reuters.com/article/2012/08/02/bristolmyers-hepatitis-idINL4E8J20H620120802
Aug 1 (Reuters) - Bristol-Myers Squibb Co said it has stopped administering an experimental drug to treat hepatitis C in a mid-stage trial due to a serious safety issue.
The cause of the safety issue and any potential relationship to the drug, known as BMS-986094, was not known, it said in a statement.
The company said it was undertaking an immediate assessment of all patients involved in the study and following an evaluation of patient data, will take appropriate action.
Bristol Myers acquired BMS-986094 through its $2.5 billion purchase of Inhibitex Inc earlier this year.
The drug belongs to a promising new type of hepatitis C medicines called nucleotide polymerase inhibitors, which work by targeting polymerase -- an enzyme essential for replication of the hepatitis C virus.